文献速递真菌感染

慢性肺曲霉病抗曲霉血清学:叙述性综述

Ins and outs of anti-Aspergillus serology in chronic pulmonary aspergillosis: a narrative review.
PubMed 文献 · Clin Microbiol Infect · 2026-08-10

该叙述性综述检索PubMed至2026年7月,评估抗曲霉IgG抗体检测在慢性肺曲霉病诊断中的性能、影响因素及随访价值。综述指出,由于抗原来源、报告单位和厂家截断值缺乏标准化,且无国际参考标准,不同检测方法间难以互换比较;气道定植、影像表型、基础疾病及曲霉种类均影响结果解读。未来应优先推进检测标准化、本地验证截断值,并评估系列血清学与影像、微生物学及治疗药物监测的联合应用。

要点

  • 抗曲霉IgG血清学是慢性肺曲霉病诊断的基石,但检测方法间缺乏标准化和互可比性。
  • 气道定植(如囊性纤维化、支气管扩张、慢阻肺、哮喘)可致IgG阳性,需结合临床鉴别。
  • 未来需推进检测标准化、本地验证截断值,并评估系列血清学联合影像与微生物学随访。

核心结论

  • 抗曲霉IgG血清学是慢性肺曲霉病诊断的基石,但检测性能与互换性尚未充分表征。
  • 检测标准化、本地验证截断值及系列血清学联合评估是未来优先方向。

研究设计与样本

  • 叙述性综述,检索PubMed至2026年7月,检索词组合包括Aspergillus、IgG、antibody、serology和chronic pulmonary aspergillosis。
  • 同时查阅制造商文档以获取检测特征。

主要发现

  • 慢性肺曲霉病接受长期抗真菌治疗者5年死亡率为三分之一至二分之一。
  • 直接镜检和常规培养重要但敏感性不足,抗曲霉IgG血清学是诊断基石。
  • 气道定植(尤其囊性纤维化、支气管扩张、慢阻肺和哮喘)可在非慢性肺曲霉病情况下出现IgG阳性。
  • 影像表型、基础疾病(尤其糖皮质激素暴露)和致病曲霉种类均影响检测敏感性。

关键数值与推荐

  • 存在多种酶免疫检测平台及免疫沉淀、免疫印迹、免疫层析等手工方法。
  • 抗原来源不统一(粗提取物与重组蛋白;烟曲霉与曲霉属)、报告单位不统一(Arbitrary Units/mL、IU/mL、mgA/L、mg/L)及厂家截断值差异,且无国际参考标准,阻碍跨检测比较。

临床怎么用

  • 抗曲霉IgG血清学用于慢性肺曲霉病诊断时需结合临床背景,警惕气道定植所致假阳性。
  • 解读结果时应考虑影像表型、基础疾病(尤其糖皮质激素暴露)及致病曲霉种类对敏感性的影响。
  • 随访中可考虑系列血清学联合影像、微生物学及治疗药物监测进行评估。

局限性

  • 检测性能与互换性尚未充分表征。
  • 缺乏国际参考标准,抗原来源、报告单位和厂家截断值不统一,妨碍跨检测比较。
  • 气道定植可致非慢性肺曲霉病情况下IgG阳性,增加解读难度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic pulmonary aspergillosis (CPA) encompasses a spectrum of progressive lung diseases occurring in patients with prior structural lung damage. Despite prolonged antifungal therapy, CPA carries a 5-year mortality of one-third to one-half. Clinical symptoms are nonspecific, and radiological signs often overlap with those of the underlying disease. Direct microscopy and conventional culture are important but insensitive. Consequently, anti-Aspergillus IgG serology is the cornerstone of CPA diagnosis. OBJECTIVES: To review available anti-Aspergillus antibody assays for CPA diagnosis, the factors affecting their performance and interpretation, and their potential role in patient follow-up. SOURCES: PubMed was searched through July 2026 using combinations of 'Aspergillus', 'IgG', 'antibody', 'serology', and 'chronic pulmonary aspergillosis'. Manufacturer documentation was also reviewed for assay characteristics. CONTENT: Multiple enzyme immunoassay platforms exist, alongside manual methods, such as immunoprecipitation, immunoblot, and immunochromatographic tests. Although anti-Aspergillus IgG is central to CPA diagnosis, assay performance and interchangeability remain incompletely characterized. The lack of standardisation in antigen sources (crude extracts versus recombinant proteins; A. fumigatus versus Aspergillus spp.), reported units (Arbitrary Units/mL, IU/mL, mgA/L, mg/L), and manufacturer cut-offs, together with the absence of an international reference standard, prevents cross-assay comparisons. In addition, interpretation is difficult because airway colonisation, particularly in cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, and asthma, may yield positive IgG results outside CPA. Moreover, radiological phenotypes, underlying conditions, notably corticosteroid exposure, and causative Aspergillus species contribute to variable sensitivities. IMPLICATIONS: Further work should prioritize assay standardisation, locally validated cut-offs, and evaluation of serial serology alongside imaging, microbiology, and therapeutic drug monitoring.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Gibert C, Maitre T, Godet C, et al. Ins and outs of anti-Aspergillus serology in chronic pulmonary aspergillosis: a narrative review. Clin Microbiol Infect. 2026. PMID: 42575279. doi:10.1016/j.cmi.2026.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。